BIOCOMBiotech CSOs, CDMOs, CROs, lab specialists and AI developers gave an in-depth insight into next-generation antibody-based therapies to about 1,500 attendees at the 16th PEGS Europe in Barcelona. Several new formats are expected to enter the market in the next few years, promising to significantly reduce the side effects of CAR-Ts, bispecific antibodies, ADCs, etc. and improve their efficacy.
Tag Archive for: Protein degraders
Phoremost LtdBritish protein degrader specialist PhoreMost Ltd has extended its €33m Series B financing to $50M and plans to advance its oncology and inflammation degrader programmes.
Draupnir Bio ApSTargeted protein degradation Draupnir Bio Aps has raised further €12m in an equitiy investment to advance its preclinical pipeline.